share_log
Benzinga ·  06/25 07:32

Unicycive Therapeutics Announced Results From The Oxylanthanum Carbonate UNI-OLC-201 Pivotal Trial, Established Favorable Tolerability And Safety And New Drug Application Submission Anticipated In Q3 2024

Unicycive Therapeutics宣布来自氧兰素碳酸盐UNI-OLC-201关键试验的结果,证实其良好的耐受性和安全性,新药申请预计将在2024年第三季度提交。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发